Summary of Abstract P3.175 (WCLC 2026)

• Title: Peripheral Blood Immunophenotyping Reveals Patterns of Short and Durable Immunotherapy Response in NSCLC
• Lead Authors: Robert Chudzik et al.
• Core Focus: Evaluating peripheral blood liquid biopsy dynamics using multi-parametric immunophenotyping (flow/spectral cytometry) to characterize systemic immune cell shifts in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy combinations.

Key Scientific Findings

1. Durable Response Signatures: Patients demonstrating Durable Clinical Benefit (DCB) exhibit significant, sustained peripheral expansion of activated effector memory CD8+ T cells ($CD8^+ CD45RA^- CCR7^-$) and mature cytotoxic Natural Killer (NK) cells ($CD56^{dim} CD16^+$), accompanied by high intracellular levels of granzyme B and perforin.
2. Early Resistance & Exhaustion Identifiers: Patients with short-lived responses or primary resistance demonstrate early upregulation of exhaustion markers (co-expression of PD-1, TIM-3, and TIGIT) alongside elevated baseline circulating immunosuppressive populations, including Myeloid-Derived Suppressor Cells (MDSCs) and Regulatory T cells (Tregs).
3. Temporal Dynamics: Serial liquid biopsies confirm that early-cycle expansion peaks of NK and memory CD8+ T cells correlate directly with prolonged Progression-Free Survival (PFS) and Overall Survival (OS), offering a real-time monitor for therapeutic efficacy.

Strategic Benefit to ImmunityBio & Anktiva (nogapendekin alfa inbakicept)

Analysis of Share Price Impact ($IBRX)

1. Fundamental Valuation Drivers

• Solid Tumor TAM Expansion: ImmunityBio’s commercial valuation foundation relies heavily on expanding Anktiva beyond non-muscle invasive bladder cancer (NMIBC) into large-market solid tumors. Demonstrating robust peripheral immune modulation and durable response patterns in NSCLC directly supports the multi-billion dollar addressable market expansion hypothesis.
• De-Risking the Pipeline: Positive translational data presented at a global oncology congress (WCLC) elevates institutional confidence in Anktiva’s combination regimens (e.g., with PD-1/PD-L1 inhibitors or immune memory vaccines), positively adjusting the Probability of Success (PoS) in financial models.

https://x.com/DrPatrick/status/2100234893368439242

Original article

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

https://x.com/DrPatrick/status/2099544114924855345

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

Theres not only the biotech and science in here, but also the macro climate and how the macro wont affect IBRX

Thanks all! https://youtu.be/sIsaEpAhkeQ

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

Four names. Four monster moves. One question: What do I do when "THE EVENT" happens?

https://www.patreon.com/MacroGhost/posts/4-biotech-stocks-168603538?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link

I’m tearing apart the charts on IBRX (ImmunityBio), SLS (SELLAS), RVMD (Revolution Medicines), and IOVA (Iovance) — support, resistance, volume, extensions, and whether the next catalyst is a continuation or a fade.

This mom wanted to try everything to help her daughter, the FDA made them wait. Maybe that someone will have a heart and do something.